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Abstract
Cisplatin is widely used as an anti-tumor drug for the treatment of solid tumors. 
Unfortunately, it causes nephrotoxicity as a critical side effect, limiting its use, given that 
no preventive drug against cisplatin-induced nephrotoxicity is currently available. This 
study identified that a previously developed drug, diphenhydramine, may provide a novel 
treatment for cisplatin-induced nephrotoxicity based on the results of the analysis of 
medical big data. We evaluated the actual efficacy of diphenhydramine via in vitro and 
in vivo experiments in a mouse model. Diphenhydramine inhibited cisplatin-induced cell 
death in renal proximal tubular cells. Mice administered cisplatin developed kidney injury 
with renal dysfunction (plasma creatinine: 0.43 ± 0.04 mg/dl vs 0.15 ± 0.01 mg/dl, 
p<0.01) and showed augmented oxidative stress, increased apoptosis, elevated 
inflammatory cytokines, and mitogen-activated protein kinases activation; however, most 
of these symptoms were suppressed by treatment with diphenhydramine. Further, the 
renal concentration of cisplatin was attenuated in diphenhydramine-treated mice 
(platinum content: 70.0 ± 3.3 μg/g dry kidney weight vs 53.4 ± 3.6 μg/g dry kidney weight, 
p<0.05). Importantly, diphenhydramine did not influence or interfere with the anti-tumor 
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effect of cisplatin in any of the in vitro or in vivo experiments. Moreover, a retrospective 
clinical study of 1467 cancer patients treated with cisplatin showed that patients who had 
used diphenhydramine exhibited less acute kidney injury than patients who had not used 
diphenhydramine (6.1 % vs 22.4 %, p<0.05). Thus, diphenhydramine demonstrated 
efficacy as a novel preventive medicine against cisplatin-induced nephrotoxicity.
Keywords: cisplatin, nephrotoxicity, diphenhydramine
Translational Statement
Cisplatin-induced nephrotoxicity remains an unresolved condition, with no preventive 
medicine available. We identified that an existing antihistamine, diphenhydramine, is a
candidate preventive medicine for cisplatin-induced nephrotoxicity based on the results 
of the analysis of medical big data. In a mouse study, cisplatin-induced nephrotoxicity
was suppressed by diphenhydramine pre-treatment, while diphenhydramine did not 
interfere with the cisplatin anti-tumor effects. A retrospective clinical study showed that 
patients with cancer who had used diphenhydramine before cisplatin treatment exhibited 
less renal dysfunction. Thus, diphenhydramine is a novel drug effective against cisplatin-
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Cisplatin (cis-diamminedichloroplatinum; CDDP) is a major anti-tumor drug 
used as a chemotherapeutic agent for a wide spectrum of human malignancies worldwide. 
Despite its beneficial effects against various cancers, patients treated with cisplatin suffer 
severe side effects; nephrotoxicity is a well-known side effect reported to occur in 25%
of patients undergoing cisplatin chemotherapy1. Although the molecular mechanism of
cisplatin-induced nephrotoxicity (CIN) involves multiple factors including inflammation, 
apoptosis, and oxidative stress2-4, no preventive drugs for CIN are available for clinical 
use. Instead, only the promotion of hydration or the administration of diuretics such as
furosemide are widely used as preventive measures prior to cisplatin-treatment5.
The Food and Drug Administration (FDA) Adverse Events Reporting System 
(FAERS) database is one of the largest global databases, containing millions of case 
reports on drug-associated adverse events; is used widely to supply real clinical data for 
pharmacovigilance6-9. Recently, the FAERS database has also been utilized to research 
drug repositioning against various diseases; indeed, certain candidate drugs have already
been found for hypertension10 and depression11. This database also allows the assessment
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the clinical implications based on basic experimental studies. We confirmed that the drug 
effect evaluated by the FAERS database analysis is consistent with the results of our 
experimental study using a mouse model12, 13. Therefore, combined analysis using both
the FAERS database and conventional experimental techniques is thought to be
advantageous for the confirmation of the “novel efficacy” of existing drugs.
In the present study, we identified that the histamine H1 receptor (H1R)
antagonist diphenhydramine (DPH) confers a preventive effect against CIN, based on 
information from the FAERS database, conventional experimental studies, and a 
retrospective clinical study.
Results
The effect of H1R antagonist on CIN as per the FAERS database
The FAERS database was used to evaluate the occurrence of CIN in patients 
concomitantly treated with the H1R antagonist. As expected, as per the FAERS database,
cases undergoing cisplatin treatment were associated with the increased occurrence of 
nephrotoxicity [ROR 3.90 (3.75–4.06)]. Next, we performed a comprehensive analysis 
of 1534 drugs used in combination with cisplatin to seek candidate drugs that reduce the 
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occurrence of nephrotoxicity. Except for anti-cancer drugs and general infusion 
components, four drugs were detected as candidates for the prevention of CIN (Table 1).
To further explore the drug candidates, we focused on DPH, a first-generation H1R 
antagonist. H1R is ubiquitously expressed in many tissues and H1R activation is involved 
in processes including inflammation14, oxidative stress15, and apoptosis14; therefore, the
H1R antagonist has the potential to exert a preventive action against CIN. In addition to 
DPH, we analyzed the occurrence of nephrotoxicity in cases treated with nine additional 
concomitantly administered first-generation H1R antagonists. As shown in Table 2, only 
DPH-treated patients showed a significantly lower prevalence of CIN. Consequently, we 
focused on DPH as a candidate drug for the prevention of CIN in subsequent experiments.
Effects of DPH against cisplatin-induced cell death in renal proximal tubular cells
We investigated whether DPH exerted a protective effect against CIN using 
HK-2 and LLC-PK1 cells in an in vitro screening experiment. As expected, the MTS 
assay showed that cisplatin treatment augmented cell death, which was significantly 
suppressed by the treatment with DPH in both cell lines (Figure 1). Similar to our findings,
a conference abstract reported that DPH treatment would protect against CIN, as per in 
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vitro data in the context of renal proximal tubule cells16. Upon determining that DPH 
prevented renal tubular cell death induced by cisplatin, we moved on to in vivo
experiments.
Effects of DPH against cisplatin-induced kidney injury in a mouse model
We examined the preventive effect of DPH against CIN in an in vivo mouse 
model. Mice treated with cisplatin exhibited reduced body weight, while no change in
kidney weight was found (Table 3). In a histological analysis, kidney injury was initially
induced in mice with cisplatin administration; however, this condition was alleviated by
the concomitant treatment with DPH (Figure 2A and B). The mRNA expression of KIM-
1 and LCN2 (markers of renal tubular damage) and the plasma BUN and creatinine levels 
were upregulated in cisplatin-administered mice, except in those co-treated with DPH
(Figure 2C and Table 3). The cisplatin-induced mRNA upregulation of inflammatory 
cytokines such as TNF- , IL-1 , IL-6, and MCP-1 was also inhibited by the treatment 
with DPH (Figure 2D). Of note, the preventive effect of DPH against CIN was observed
in a dose-dependent manner; however 20 md/kg DPH led to almost the same protective 
degree as 40 mg/kg DPH (Supplemental Figure S1). The mRNA expression of the 
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histamine H1 receptor was reduced by cisplatin treatment and was unchanged after DPH 
co-administration (Supplemental Figure S2). Dihydroethidium (DHE) staining and 4-
hydroxynonenal (HNE) expression, induced by cisplatin, were also inhibited by the
administration of DPH (Figure 3A and C). In terms of apoptosis, cisplatin augmented 
TUNEL positive cells and cleaved caspase-3 expression in the kidneys; this expression
declined under DPH treatment (Figure 3B and C). Moreover, cisplatin-induced 
phosphorylation in the context of the JNK and ERK1/2 signaling pathways was
suppressed by the DPH treatment (Figure 3D). Cisplatin also increased the 
phosphorylation of p38MAPK, which was not inhibited by DPH (Figure S3). These 
results suggest that the preventive effect of DPH in cisplatin-induced kidney injury
involve the inhibition of the inflammatory response, oxidative stress, and apoptosis.
Additionally, we evaluated leukocytes populations via IHC using macrophage (F4/80), 
neutrophil (Ly-6G/C), lymphocyte (T cell, CD3) and eosinophil (toluidine blue and c-kit)
markers. Te accumulation of macrophages and lymphocytes was decreased in the kidneys 
of cisplatin-treated mice with or without DPH. On the other hand, the accumulation of 
neutrophils was increased in the kidneys of cisplatin-treated mice, and suppressed by 
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DPH. Mast cells were almost not detected in the kidneys of mice treated (or not) with 
cisplatin/DPH by c-kit IHC as per toluidine blue staining (Supplemental Figure S4). The 
mRNA expression levels of F4/80, Ly-6g, CD3, c-kit were also not elevated by cisplatin 
administration (Supplemental Figure S5). The preventive effect of DPH on inflammation 
might partly involve the prevention of cisplatin-induced neutrophils accumulation in 
addition to the direct inhibition of oxidative stress via platinum uptake into renal tubules.
Importantly, the administration of cisplatin caused a reduction in the survival rate of mice;
all mice died by day 6. On the other hand, DPH-treated mice showed a higher survival 
rate compared to that of vehicle treated mice 14 days after cisplatin administration (73% 
vs. 0 %, P < 0.01) (Supplemental Figure S6).
Involvement of the histamine H1 receptor in CIN
We checked the role of the H1R against CIN using H1R gene knockout KO
(KO) mice. The increased BUN and plasma creatinine levels as well as renal injury 
(assessed by histological changes and KIM-1 and LCN2 mRNA expression) induced by 
CIN were not evident in H1RKO mice (compared to wild-type (WT) mice; Table 4 and 
Figure 4A, B, and C). The cisplatin-induced IL-6 and IL-1 mRNA levels were also 
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inhibited in H1RKO mice; however, the expression of TNF- and MCP-1 was not 
inhibited (Figure 4D). Cisplatin-induced oxidative stress and apoptosis, as well as 
ERK1/2 and JNK activation, were also attenuated in H1RKO mice (versus WT mice;
Figure 4E-H). Importantly, the degree of prevention against CIN was more effective in 
WT mice under DPH treatment than in H1RKO mice. Therefore the action of DPH 
against CIN is probably not only mediated by the H1R pathway, but also by other 
mechanisms.
The effect of DPH on the platinum levels in the kidneys, plasma, whole blood, and urine
In the kidneys, the cisplatin uptake into renal tubular cells is mediated by organ 
cation transporter 2 (OCT2); cisplatin accumulates, resulting in nephrotoxicity17, 18.
Interestingly, DPH has previously been reported to inhibit OCT219, 20. To evaluate the
DPH action on cisplatin pharmacodynamics within the body, we measured the platinum 
levels in whole blood, plasma, and the kidneys following cisplatin administration. As 
shown in Tables 5 and 6, renal and plasma platinum levels were reduced by 
approximately 75% at both 10 min and 8 h after cisplatin treatment in mice treated with
DPH. The plasma-free platinum concentration was also lower after cisplatin 
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administration in mice under DPH treatment. Conversely, no differences in platinum 
concentration were found in the whole blood of both control and DPH-treated mice, 10
min and 8 h after cisplatin administration. On the other hand, the concentration of 
platinum in clots (contained more than 90% red blood cells) was higher in mice under
DPH treatment at both 10 min and 8 h after cisplatin administration. These findings 
suggest that DPH might promote the binding of cisplatin to blood cells, contributing to 
the reduction in the platinum incorporated into the kidneys. In addition, there was no 
significant differences in urinary platinum excretion regardless of DPH treatment, 
indicating no effect of DPH on the urinary excretion of cisplatin.
Effects of DPH against CIN in H1RKO mice 
We examined whether DPH could exert further preventive action against CIN 
in H1RKO mice. DPH still alleviated the cisplatin-induced aggravation of BUN, plasma 
creatinine, renal injury, and inflammatory cytokines including TNF- and MCP-1 in 
H1RKO mice (Figure 5A-D). Of note, there was no difference in the renal OCT2 
expression and renal cisplatin content between WT and H1RKO mice (Figure 5E and 
Supplemental Table S1). Moreover, cisplatin-induced DNA damage, as well as the 
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increment of the platinum content, were also suppressed by DPH treatment in H1RKO 
mice (Figure 5F and G). These findings suggest that the action of DPH against CIN is 
mediated by both the H1R-dependent and -independent mechanisms.
Effect of DPH in tumor-bearing mice under cisplatin treatment
DPH suppressed CIN; however, it was unclear whether DPH would diminished
the cytotoxic effects of cisplatin in a cancer model. To address this, we tested the effect 
of DPH on the cisplatin anti-tumor action using cancer cell lines. As depicted in Figure 
6, cisplatin-induced cell death was not inhibited by the concomitant treatment with DPH 
in 3LL cells, MKN45 cells, colon26 cells, and HeLa cells, suggesting no inhibitory effect 
of DPH on the anti-tumor properties of cisplatin in vitro. OCT2 was not expressed in 
these tumor cell lines, indicating the intake of cisplatin can be mediated by a transporter 
other than OCT2 (Supplemental Figure S7). We further examined the effect of DPH on
the anti-tumor action of cisplatin using a 3LL-cell in vivo xenograft mouse model. During 
the four week observation period, the saline control group showed continuous tumor 
growth, whereas the two drug-treated groups exhibited suppression of tumor growth;
however, no difference in the cisplatin anti-tumor effect was found for in mice with or 
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without DPH treatment (Figure 7A). Moreover at the end of the four week study-period,
mice under the vehicle treatment showed a significant increase in tumor weight and 
volume compared to mice treated with cisplatin and cisplatin + DPH. Of note, no
differences in tumor volume and weight were observed between the cisplatin-treated and
the cisplatin + DPH-treated animals (Figure 7B). Despite tumor growth, mice in the
vehicle treatment group did not develop renal dysfunction as evidenced by the plasma
creatinine levels. In contrast, the plasma creatinine levels of the cisplatin-treated group 
nearly doubled, whereas the group treated with cisplatin plus DPH exhibited a
significantly improved renal function (Table 7). Furthermore, cisplatin-induced kidney 
injury as indicated by histology and the mRNA levels of renal damage markers was
attenuated by the DPH treatment (Figure 7C and D). Repeated cisplatin administration 
induced renal fibrosis, which was also inhibited in the context of the concomitant
treatment with DPH (Figure 7E and F). Therefore, DPH prevents CIN without affecting
the anti-tumor action of cisplatin.
Retrospective clinical study of cancer patients receiving DPH before cisplatin-treatment
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A total of 1467 patients, consisting of 1416 DPH non-users and 51 DPH users, were 
enrolled in this study (Supplemental Figure S8). The clinical characteristics of patients 
included in the analysis are listed in Table 8. The characteristics of patients differed in 
the non-DPH and the DPH groups. Particularly, the main problem was the difference in 
creatinine clearance profiles, mainly due to the fact that almost all DPH users were female 
patients. Of note, in the FEARS analysis, there was no significant differences in RORs
between males and females with respect to the preventive effect of DPH on CIN
(Supplemental Table S2). As opposed to the entire population, the propensity-matched 
patients (49 in each group) showed similar group characteristics. The incidence of AKI 
was 6.1% and 22.4% in patients undergoing and not-undergoing DPH treatment, 
respectively, before the administration of cisplatin (P = 0.04) (Table 9). Overall, these 
results suggest that cisplatin-induced AKI is suppressed in patients under
diphenhydramine treatment.
Discussion
We identified DPH as a preventive drug for CIN using the FAERS database.
DPH was also confirmed to prevent CIN in experimental studies; of note DPH was 
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confirmed to prevent CIN without affecting the anti-tumor effect of cisplatin. Moreover, 
the clinical cohort study revealed that the previous usage of DPH suppressed acute kidney 
injury in patients undergoing cisplatin treatment. Thus, our results identify DPH as a
potential drug candidate for the prevention of CIN.
Previous studies have shown the involvement of inflammation, apoptosis, and 
oxidative stress in CIN; their inhibition led to the amelioration of CIN2-4. The present 
study clarified that DPH pre-treatment reduced cisplatin-induced renal damage via the
inhibition of the increase of inflammatory cytokines, apoptosis, and oxidative stress in a
mouse model. Cisplatin also activated the MAP kinase pathways including ERK1/2, JNK, 
and p38MAPK. On the other hand, DPH treatment inhibited the cisplatin-induced 
activation of ERK1/2 and JNK, but not of p38MAPK. Thus, the inhibition of the MAPK
pathways was probably behind the reduction of apoptosis and inflammation, contributing
to the suppression of CIN21-23.
H1R is ubiquitously expressed in many tissues and cells, mediating numerous 
histamine-induced symptoms via various signaling pathways24. In fact, the histamine-
histamine receptor mediated pathway plays a crucial role in the progression of end-organ 
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tissue injury, including in kidneys25. The administration of platinum agents also causes 
hypersensitivity reactions26, suggesting an action of cisplatin on H1R-mediated responses.
H1R activation is also involved in the following processes: inflammation14, oxidative 
stress15, and apoptosis14. Therefore, the H1R antagonist might exert a preventive action 
against CIN through the inhibition of inflammation, apoptosis, and oxidative stress.
Indeed, H1R-deficient mice exhibited lower degrees of CIN compared to those in WT 
mice; nevertheless no difference was seen with respect to the renal platinum content,
thereby indicating the preventive action of the H1R antagonist against CIN. Therefore,
pharmacological inhibition or gene knockout of H1R alleviated CIN through the 
suppression of inflammation, oxidative stress, and apoptosis. However, the degree of CIN 
prevention was stronger in H1RKO mice under DPH treatment; DPH exerted increased 
preventive effect against CIN in H1RKO mice. Thus, DPH may also induce an alternative
effect not dependent on the inhibition of H1R.
CIN is caused by the accumulation of cisplatin in the proximal tubules of the 
kidneys; it accumulates in the renal cortex in concentrations five-fold higher than those
in serum27 and locates primarily in the S3 segment of renal proximal tubules28. OCT2 is 
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specifically expressed in the basal membranes of proximal tubular cells29 and is 
responsible for the uptake of cisplatin18. CIN was inhibited in OCT1/2-deficient mice30,
indicating a target for the prevention of CIN. Interestingly, DPH has been shown to inhibit
OCT219, 20. Therefore, we surmised that the suppressive effect of DPH was mediated 
through the prevention of the uptake of cisplatin via OCT2. As expected, DPH 
pretreatment reduced approximately 75% of the platinum concentration in the kidneys of
mice under cisplatin treatment. However, the plasma platinum concentration, as well as
the free platinum concentration, were also lower in mice under DPH treatment, 10 min 
after cisplatin administration, whereas no differences in the platinum concentration were
found in whole blood samples between both groups, suggesting that DPH induced 
cisplatin to bind to blood cells.
Once cisplatin is administered, approximately 98% of the drug immediately 
binds to plasma proteins including transferrin, -globulin, and albumin31. However, other 
studies reported that the severity of CIN was related to the peak plasma cisplatin
concentration and/or the area under the plasma cisplatin concentration-time curve for
unbound cisplatin32-34. In cancer patients treated with cisplatin, the concentration of 
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cisplatin in whole blood was 10, 500, and 100 ng Pt/mL in plasma, plasma proteins, and 
hemoglobin, respectively35. Thus, cisplatin was also distributed to the blood cell 
compartment (nearly all red blood cells). We analyzed platinum levels of the clot as an 
alternative to red blood cells because the clots contain more than 90% red blood cells. 
The concentration of clot platinum was higher in mice under DPH treatment at both 10 
min and 8h after cisplatin administration. These findings indicate that DPH promotes the 
binding of cisplatin to red blood cells. Moreover, no differences in urinary platinum 
excretion were seen in mice administered cisplatin with or without DPH treatment. DPH 
may facilitate the binding of cisplatin to the red blood cell compartment, thereby 
attenuating the plasma cisplatin concentration as well as the intake of cisplatin to the
proximal tubules without affecting urinary excretion.
The anti-tumor effect of cisplatin was reported to be exerted in its free form,
unbound to proteins36. However, another study reported that transferrin-bound cisplatin 
showed an enhanced anti-tumor efficacy and produced fewer side effects compared to 
free cisplatin37. Although it remains controversial whether the free form or the protein-
bound form of cisplatin exerts the primary anti-tumor effect, in the present study, DPH 
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did not prevent the anti-tumor effect of cisplatin in either in vitro or in vivo experiments. 
Especially in the in vivo experiment, the unfettered anti-tumor effect of cisplatin may be 
due to the stability of its concentration in whole blood with or without DPH. Our findings 
suggest that DPH prevents CIN without affecting the anti-tumor efficacy of cisplatin.
We further investigated the effects of DPH in the context of CIN in a 
retrospective clinical study and found that DPH treatment significantly reduced the 
occurrence of AKI following cisplatin treatment in patients with cancer. Antihistamine 
drugs have been used as premedication for the prevention of chemotherapy-related 
hypersensitivity reactions in clinical settings worldwide38; in fact, DPH has been used 
clinically as a premedication drug for the combination therapy regimen of cisplatin and 
paclitaxel in patients with advanced-stage epithelial ovarian cancer39 or head and neck 
squamous cell carcinoma40. Therefore, our results suggest that the premedication with 
DPH brings the additional advantage of the prevention of CIN. This said, there were 
limitations in the present study. The DPH user group included a greater number of young 
females, with lower serum creatinine levels at baseline. Therefore, we used a propensity 
score analysis to exclude the potential confounding factors and selection biases in sample 
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size including marked gender differences between the groups. At the same time, the 
FEARS analysis showed no significant differences in ROR between males and females
in the preventive effect of DPH on CIN. Although our results support the preventive effect 
of DPH against CIN, as per the findings of the FAERS database analysis and basic 
experimental studies, further research is necessary to confirm the preventive effect of 
DPH against CIN.
In conclusion, a novel activity was revealed for DPH, a potential preventive 
medicine against CIN; therefore drug repositioning should be considered (and is expected 
to be easy since DPH is already administered to cancer patients undergoing 
chemotherapy). A prospective study is required to clarify the potential of DPH as a 
preventive treatment for CIN in the future. 
Methods
Analysis of the FAERS database
Adverse event records from January 2004 to September 2017 were obtained 
from the FDA web site (www.fda.gov ). The adverse event terms corresponded to the 
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Medical Dictionary for Regulatory Activities (MedDRA). The MySQL software (version 
5.7.21) was used to build a database integrating the FAERS data1. The adverse event risk 
signal was evaluated via the calculation of the reporting odds ratio (ROR) with a 95% 
confidence interval (CI) 12, 41-44. The inverse risk signal was considered significant when 
the ROR and the upper limit of the corresponding 95% CI were <1. 
Cell culture and cell death assay
Proximal tubule cell lines were obtained from the American Type Culture 
Collection (Virginia, USA) and the Japanese Collection of Research Bioresources Cell 
Bank (Osaka, Japan). Cancer cell lines were obtained from the Japanese Collection of 
Research Bioresources Cell Bank. Cell death was assessed as described previously 45.
Animal model of cisplatin-induced nephrotoxicity
Seven to eight-week-old male C57BL/6J mice were purchased from Nippon 
CLEA (Tokyo, Japan). H1RKO mice (genetic background: C57BL/6J) were purchased 
from Oriental Bio Service Inc.(Kyoto, Japan)46. Mice with nephrotoxicity induced by 
cisplatin (20 mg per kg) were administered with DPH (20 mg per kg) or vehicle. 
Histological analysis
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The histological evaluation of renal tubular damage has been described 
previously 47. The picrosirius red staining was used for the evaluation of renal fibrosis as 
previously described 45.
Immunohistochemistry
Frozen sections were used for the detection of Platinum-(GpG) DNA adducts 
and visualized using immunofluorescence (Alexa fluor; Life Technology, Tokyo, Japan) 
as previously described in detail44. Paraformaldehyde-fixed paraffin-embedded sections 
were used for immunohistochemistry of leukocytes as previously described 48.
Measurement of the platinum concentration
The kidney, plasma, whole blood, clot, and urine samples were incubated at 
95°C for 1 h with 60% nitric acid (28163-1B, Kanto Kagaku Co., Tokyo, Japan). The 
lysate was centrifuged and the supernatant was used for the measurement of platinum 
content.
Tumor-bearing mouse model
3LL cells (5 × 106 cells per site) were subcutaneously injected on the right flank 
of mice, and the tumor growth was routinely monitored using a vernier caliper. The mice
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were randomly divided into three groups for weekly intraperitoneal treatment with 
cisplatin, cisplatin plus DPH, or vehicle (control).
Retrospective clinical study
We retrospectively reviewed the medical charts of patients who were
administered cisplatin at Tokushima University Hospital between 2008 and 2019. All 
patients had received their first course of chemotherapy with cisplatin. 
Statistical analysis of experimental studies
Data are presented as the mean ± standard error of the mean (mean ± SEM) in 
the form of dot plots. For data not normally distributed, data are presented as the median 
with the interquartile range. The Mann–Whitney U test or t-test were used for comparison 
between two groups. The Kruskal–Wallis test was used for comparisons between more 
than two groups, and the statistical significance of each difference was evaluated. 
Survival curves were created using the Kaplan-Meier method and tested using a log-rank 
test. Incidence was compared by means of the Fisher’s exact test. Statistical significance 
was indicated by P < 0.05.  
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Supplementary Materials
1. Supplemental materials and methods
2. Supplemental Tables
Supplemental Table S1. Effect of each drugs on the occurrence of cisplatin-induced renal 
disorder by FAERS analysis. 
Supplemental Table S2. Search terms for renal disorder-related adverse events in the 
analysis of FAERS. 
Supplemental Table S3. Platinum content in kidney, plasma, whole blood at 10m after 
CDDP treatment in WT mice and Hrh1KO mice.
Supplemental Table S4. Primer sequences.
3. Supplemental Figures
Supplemental Figure S1. Dose-dependency of DPH against CIN. Quantitative analysis of 
mRNA expression in the kidneys of mice in each group. Values are expressed as mean ± 
SEM. *P < 0.05, **P < 0.01, n =5-9 in each group.
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Supplemental Figure S2. Quantitative analysis of mRNA expression, immunohistological 
analysis, and protein expression in the kidneys of mice in each group. Values are 
expressed as mean ± SEM. *P < 0.05, **P < 0.01, n =5-9 in each group.
Supplemental Figure S3. Left panel: Representative protein bands of phospho-p38MAPK, 
-actin in the kidneys of mice. Right panel: Semi-quantitative 
analysis of densitometry for p38MAPK phosphorylation. Values are expressed as mean 
± SEM, *P < 0.05, **P < 0.01, n = 5 in each group.
Supplemental Figure S4. The effect of cisplatin with or without DPH on leukocytes 
populations in the kidney. Left panel: representative immunohistochemistry of F4/80, Ly-
6g, CD3, toluidine blue and c-kit in the kidneys of mice in each group. Right panel: semi-
quantitative analysis of F4/80, Ly-6g, and CD3 positive cells. Values are expressed as 
mean ± SEM, *P < 0.05, n = 4–5 in each group. Arrow heads; c-kit positive cells.
Supplemental Figure S5. mRNA expression levels of F4/80, Ly-6g, CD3, and c-kit in the 
kidneys of mice in each group. Values are expressed as mean ± SEM. *P < 0.05, **P < 
0.01, n = 8–9 in each group.
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Supplemental Figure S6. Survival rates of mice with vehicle or DPH treatment after 
cisplatin administration. Survival rates were calculated by the Kaplan-Meier method 
and compared by the log-lank test. n=11 in each group.  
Supplemental Figure S7. Left panel; Representative PCR product bands of OCT2, H1R, 
and 36B4 in KH-2 and LLC-PK1. Right panel; Representative PCR product bands of 
OCT2 and 36B4 in human kidney, mouse kidney, and various cancer cell lines.
Supplemental Figure S8. Flow chart of patient selection.
Supplementary information is available on Kidney International's website.
32  
References
1. Campbell AB, Kalman SM, Jacobs C. Plasma platinum levels: relationship to cisplatin 
dose and nephrotoxicity. Cancer Treat Rep 1983; 67: 169-172.
2. Pabla N, Dong Z. Cisplatin nephrotoxicity: mechanisms and renoprotective strategies. 
Kidney Int 2008; 73: 994-1007.
3. Miller RP, Tadagavadi RK, Ramesh G, et al. Mechanisms of Cisplatin nephrotoxicity. 
Toxins (Basel) 2010; 2: 2490-2518.
4. Ozkok A, Edelstein CL. Pathophysiology of cisplatin-induced acute kidney injury. 
Biomed Res Int 2014; 2014: 967826.
5. Santoso JT, Lucci JA, 3rd, Coleman RL, et al. Saline, mannitol, and furosemide hydration 
in acute cisplatin nephrotoxicity: a randomized trial. Cancer Chemother Pharmacol 2003; 
52: 13-18.
6. Kadoyama K, Sakaeda T, Tamon A, et al. Adverse event profile of tigecycline: data 
mining of the public version of the U.S. Food and Drug Administration adverse event 
reporting system. Biol Pharm Bull 2012; 35: 967-970.
7. Tamura T, Sakaeda T, Kadoyama K, et al. Aspirin- and clopidogrel-associated bleeding 
complications: data mining of the public version of the FDA adverse event reporting 
system, AERS. Int J Med Sci 2012; 9: 441-446.
8. Hoffman KB, Kraus C, Dimbil M, et al. A survey of the FDA's AERS database regarding 
muscle and tendon adverse events linked to the statin drug class. PLoS One 2012; 7: 
e42866.
9. Sakaeda T, Tamon A, Kadoyama K, et al. Data mining of the public version of the FDA 
Adverse Event Reporting System. Int J Med Sci 2013; 10: 796-803.
33  
10. Wang K, Wan M, Wang RS, et al. Opportunities for Web-based Drug Repositioning: 
Searching for Potential Antihypertensive Agents with Hypotension Adverse Events. J 
Med Internet Res 2016; 18: e76.
11. Hashikawa N, Utaka Y, Ogawa T, et al. HSP105 prevents depression-like behavior by 
increasing hippocampal brain-derived neurotrophic factor levels in mice. Sci Adv 2017; 
3: e1603014.
12. Horinouchi Y, Ikeda Y, Fukushima K, et al. Renoprotective effects of a factor Xa 
inhibitor: fusion of basic research and a database analysis. Sci Rep 2018; 8: 10858.
13. Izawa-Ishizawa Y, Imanishi M, Zamami Y, et al. Development of a novel aortic 
dissection mouse model and evaluation of drug efficacy using in-vivo assays and 
database analyses. J Hypertens 2018.
14. Bakker RA, Schoonus SB, Smit MJ, et al. Histamine H(1)-receptor activation of nuclear 
factor-kappa B: roles for G beta gamma- and G alpha(q/11)-subunits in constitutive and 
agonist-mediated signaling. Mol Pharmacol 2001; 60: 1133-1142.
15. Rocha SM, Saraiva T, Cristovao AC, et al. Histamine induces microglia activation and 
dopaminergic neuronal toxicity via H1 receptor activation. J Neuroinflammation 2016; 
13: 137.
16. Hanigan MH, Xu G. Diphenhydramine protects against cisplatin-induced nephrotoxicity. 
Proc Amer Assoc Cancer Res 2006; 47: Conference abstract.
17. Yonezawa A, Masuda S, Nishihara K, et al. Association between tubular toxicity of 
cisplatin and expression of organic cation transporter rOCT2 (Slc22a2) in the rat. 
Biochem Pharmacol 2005; 70: 1823-1831.
18. Ciarimboli G, Ludwig T, Lang D, et al. Cisplatin nephrotoxicity is critically mediated via 
the human organic cation transporter 2. Am J Pathol 2005; 167: 1477-1484.
34  
19. Muller J, Lips KS, Metzner L, et al. Drug specificity and intestinal membrane localization 
of human organic cation transporters (OCT). Biochem Pharmacol 2005; 70: 1851-1860.
20. Zolk O, Solbach TF, Konig J, et al. Structural determinants of inhibitor interaction with 
the human organic cation transporter OCT2 (SLC22A2). Naunyn Schmiedebergs Arch 
Pharmacol 2009; 379: 337-348.
21. Jo SK, Cho WY, Sung SA, et al. MEK inhibitor, U0126, attenuates cisplatin-induced 
renal injury by decreasing inflammation and apoptosis. Kidney Int 2005; 67: 458-466.
22. Francescato HD, Costa RS, Junior FB, et al. Effect of JNK inhibition on cisplatin-induced 
renal damage. Nephrol Dial Transplant 2007; 22: 2138-2148.
23. Ramesh G, Reeves WB. p38 MAP kinase inhibition ameliorates cisplatin nephrotoxicity 
in mice. Am J Physiol Renal Physiol 2005; 289: F166-174.
24. Akdis CA, Simons FE. Histamine receptors are hot in immunopharmacology. Eur J 
Pharmacol 2006; 533: 69-76.
25. Hattori M, Yamazaki M, Ohashi W, et al. Critical role of endogenous histamine in 
promoting end-organ tissue injury in sepsis. Intensive Care Med Exp 2016; 4: 36.
26. Makrilia N, Syrigou E, Kaklamanos I, et al. Hypersensitivity reactions associated with 
platinum antineoplastic agents: a systematic review. Met Based Drugs 2010; 2010.
27. Safirstein R, Miller P, Guttenplan JB. Uptake and metabolism of cisplatin by rat kidney. 
Kidney Int 1984; 25: 753-758.
28. Safirstein R, Winston J, Goldstein M, et al. Cisplatin nephrotoxicity. Am J Kidney Dis 
1986; 8: 356-367.
29. Motohashi H, Sakurai Y, Saito H, et al. Gene expression levels and immunolocalization 
of organic ion transporters in the human kidney. J Am Soc Nephrol 2002; 13: 866-874.
35  
30. Ciarimboli G, Deuster D, Knief A, et al. Organic cation transporter 2 mediates cisplatin-
induced oto- and nephrotoxicity and is a target for protective interventions. Am J Pathol 
2010; 176: 1169-1180.
31. Horiuchi M IY, Kohno N, Mashino S, Fujii M. Pharmacokinetics of cis-
dichlorodiammineplatinum (II). Gan To Kagaku Ryoho 1982; 9: 632-637.
32. Reece PA, Stafford I, Russell J, et al. Creatinine clearance as a predictor of ultrafilterable 
platinum disposition in cancer patients treated with cisplatin: relationship between peak 
ultrafilterable platinum plasma levels and nephrotoxicity. J Clin Oncol 1987; 5: 304-309.
33. Nagai N, Kinoshita M, Ogata H, et al. Relationship between pharmacokinetics of 
unchanged cisplatin and nephrotoxicity after intravenous infusions of cisplatin to cancer 
patients. Cancer Chemother Pharmacol 1996; 39: 131-137.
34. Nagai N, Ogata H. Quantitative relationship between pharmacokinetics of unchanged 
cisplatin and nephrotoxicity in rats: importance of area under the concentration-time 
curve (AUC) as the major toxicodynamic determinant in vivo. Cancer Chemother 
Pharmacol 1997; 40: 11-18.
35. Mustonen R, Hemminki K, Alhonen A, et al. Determination of cisplatin in blood 
compartments of cancer patients. IARC Sci Publ 1988: 329-332.
36. Takahashi K, Seki T, Nishikawa K, et al. Antitumor activity and toxicity of serum 
protein-bound platinum formed from cisplatin. Jpn J Cancer Res 1985; 76: 68-74.
37. Peng H, Jin H, Zhuo H, et al. Enhanced antitumor efficacy of cisplatin for treating ovarian 
cancer in vitro and in vivo via transferrin binding. Oncotarget 2017; 8: 45597-45611.
38. Lenz HJ. Management and preparedness for infusion and hypersensitivity reactions. 
Oncologist 2007; 12: 601-609.
36  
39. McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophosphamide and cisplatin compared 
with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl 
J Med 1996; 334: 1-6.
40. Shin DM, Glisson BS, Khuri FR, et al. Phase II trial of paclitaxel, ifosfamide, and 
cisplatin in patients with recurrent head and neck squamous cell carcinoma. J Clin Oncol 
1998; 16: 1325-1330.
41. Nagashima T, Shirakawa H, Nakagawa T, et al. Prevention of antipsychotic-induced 
hyperglycaemia by vitamin D: a data mining prediction followed by experimental 
exploration of the molecular mechanism. Sci Rep 2016; 6: 26375.
42. Suzuki Y, Suzuki H, Umetsu R, et al. Analysis of the Interaction between Clopidogrel, 
Aspirin, and Proton Pump Inhibitors Using the FDA Adverse Event Reporting System 
Database. Biol Pharm Bull 2015; 38: 680-686.
43. Ueda N, Umetsu R, Abe J, et al. Analysis of Neuropsychiatric Adverse Events in Patients 
Treated with Oseltamivir in Spontaneous Adverse Event Reports. Biol Pharm Bull 2015; 
38: 1638-1644.
44. Oshima Y, Tanimoto T, Yuji K, et al. EGFR-TKI-Associated Interstitial Pneumonitis in 
Nivolumab-Treated Patients With Non-Small Cell Lung Cancer. JAMA Oncol 2018; 4:
1112-1115.
45. Ikeda Y, Satoh A, Horinouchi Y, et al. Iron accumulation causes impaired myogenesis 
correlated with MAPK signaling pathway inhibition by oxidative stress. FASEB J 2019; 
33: 9551-9564.
46. Inoue I, Yanai K, Kitamura D, et al. Impaired locomotor activity and exploratory 
behavior in mice lacking histamine H1 receptors. Proc Natl Acad Sci U S A 1996; 93: 
13316-13320.
37  
47. Li J, Gui Y, Ren J, et al. Metformin Protects Against Cisplatin-Induced Tubular Cell 
Apoptosis and Acute Kidney Injury via AMPKalpha-regulated Autophagy Induction. Sci 
Rep 2016; 6: 23975.
48. Ikeda Y, Horinouchi Y, Hamano H, et al. Dietary iron restriction alleviates renal 
tubulointerstitial injury induced by protein overload in mice. Sci Rep 2017; 7: 10621.
38  
Figure legends
Figure 1. Inhibitory effect of diphenhydramine (DPH) on cisplatin-induced renal proximal 
tubular cell death. Cisplatin-induced cell death was attenuated by DPH treatment in HK-2 and 
LCC-PK1 cells. Values are expressed as the mean ± SEM, n = 8–12 in each group. **P < 0.01.
Figure 2. DPH inhibits cisplatin-induced nephrotoxicity in mice. (A) Representative hematoxylin 
and eosin (H&E) staining of kidney sections from control mice, cisplatin-injected mice with 
vehicle or DPH treatment. (B) Quantitative analysis of the renal tubular damage scores. Values 
are expressed as the mean ± SEM. *P < 0.05, **P < 0.01; n = 5 in each group. (C) mRNA 
expression levels of kidney injury markers (KIM-1 and lipocalin-2) in the kidneys of mice in each 
group. Values are expressed as the mean ± SEM. *P < 0.05, **P < 0.01, n = 8–9 in each group. 
(D) DPH prevents the cisplatin-induced upregulation of renal inflammation. Quantitative analysis
of mRNA expression of inflammatory cytokines in the kidneys of mice in each group. Values are
expressed as the mean ± SEM. *P < 0.05, **P < 0.01, n =8–9 in each group. The effect of DPH 
against cisplatin-induced DNA damage. (E) Left panel: Representative immunohistological 
images of DNA platination product Pt-(GpG) and DAPI in the kidney sections from cisplatin-
injected mice with vehicle and DPH treatment. Right panels: Semi-quantitative analysis of Pt-
(GpG) in DNA. Values are expressed as the mean ± SEM. *P < 0.05, **P < 0.01; n = 5 in each 
group.
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Figure 3. The effect of DPH on oxidative stress, apoptosis, and the mitogen-activated protein 
kinase pathway induced by cisplatin. (A) Left panel: representative images of dihydroethidium 
(DHE) staining in the kidneys of mice in each group. Right panel: semi-quantitative analysis of 
DHE fluorescence intensity. Values are expressed as the mean ± SEM, *P < 0.05, n = 4–5 in each 
group. (B) Left panel: representative images of TdT-mediated dUTP nick end labeling (TUNEL) 
staining in the kidneys of mice in each group. Right panel: semi-quantitative analysis of TUNEL 
positive cells. Values are expressed as the mean ± SEM, *P < 0.05, n = 4–5 in each group. (C) 
Left panel: representative protein bands of 4-hydroxynonenal (HNE), cleaved caspase- -
actin in the kidneys of mice. Right panel: semi-quantitative analysis of densitometry for 4-HNE 
and cleaved caspase-3. Values are expressed as the mean ± SEM, *P < 0.05, **P < 0.01, n = 5 in 
each group. (D) Left panel: representative protein bands of phospho-c-jun N-terminal kinase 
(JNK), total JNK, phospho-extracellular signal- -
actin in the kidneys of mice. Right panel: semi-quantitative analysis of densitometry for JNK and 
ERK1/2 phosphorylation. Values are expressed as the mean ± SEM, *P < 0.05, **P < 0.01, n = 
5 in each group.
Figure 4. Attenuated cisplatin-induced nephrotoxicity in H1R-deficient mice. (A) Representative 
hematoxylin and eosin (H&E) staining of the kidney sections from WT mice, H1RKO mice, 
cisplatin-injected WT mice, and cisplatin-injected H1RKO mice. (B) Quantitative analysis of 
renal tubular damage scores. Values are expressed as the mean ± SEM. *P < 0.05, **P < 0.01; n 
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= 7 in each group. (C) mRNA expression levels of kidney injury markers (KIM-1 and lipocalin-
2) in the kidneys of mice in each group. Values are expressed as the mean ± SEM. *P < 0.05, **P 
< 0.01, n = 7–10 in each group. (D) Effect of H1R-deficiency on cisplatin-induced upregulation 
of renal inflammatory cytokines. Quantitative analysis of mRNA expression of inflammatory 
cytokines in the kidneys of mice in each group. Values are expressed as the mean ± SEM. *P < 
0.05, **P < 0.01, n = 7–10 in each group. (E) Left panel: representative images of 
dihydroethidium (DHE) staining in the kidneys of mice in each group. Right panel: semi-
quantitative analysis of DHE fluorescence intensity. Values are expressed as the mean ± SEM, 
*P < 0.05, n = 4–7 in each group. (F) Left panel: representative images of TdT-mediated dUTP 
nick end labeling (TUNEL) staining in the kidneys of mice in each group. Right panel: semi-
quantitative analysis of TUNEL positive cells. Values are expressed as the mean ± SEM, *P < 
0.05, n = 4–5 in each group. (G) Upper panel: representative protein bands of 4-hydroxynonenal 
(HNE), cleaved caspase- -actin in the kidneys of mice. Right panel: semi-quantitative 
analysis of densitometry for 4-HNE and cleaved caspase-3. Values are expressed as the mean ± 
SEM, *P < 0.05, **P < 0.01, n = 7–10 in each group. (H) Upper panel: representative protein 
bands of phospho-JNK, total JNK, phospho- ERK1 -actin in the kidneys 
of mice. Right panel: semi-quantitative analysis of densitometry for JNK and ERK1/2 
phosphorylation. Values are expressed as the mean ± SEM, *P < 0.05, **P < 0.01, n = 7–10 in 
each group.
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Figure 5. Effect of DPH on cisplatin-induced nephrotoxicity in H1R-deficient mice. (A) Plasma 
BUN and creatinine levels. Values are expressed as the mean ± SEM. *P < 0.05, **P < 0.01; n = 
9–11 in each group. (B) Left panel: representative hematoxylin and eosin (H&E) staining of 
kidney sections in H1RKO mice with cisplatin or cisplatin plus DPH treatment. Right panel:
quantitative analysis of renal tubular damage scores. Values are expressed as the mean ± SEM. 
*P < 0.05, **P < 0.01; n = 7 in each group. (C) mRNA expression levels of kidney injury markers 
(KIM-1 and lipocalin-2) in the kidneys of mice in each group. Values are expressed as the mean 
± SEM. *P < 0.05, **P < 0.01, n = 7 in each group. (D) Effect of DPH on cisplatin-induced 
upregulation of renal inflammatory cytokines in H1RKO mice. Quantitative analysis of mRNA 
expression of inflammatory cytokines in the kidneys of mice in each group. Values are expressed 
as the mean ± SEM. *P < 0.05, **P < 0.01, n = 7 in each group. (E) Left panel: representative 
protein b -actin in the kidneys of mice. Right panel: semi-quantitative analysis 
via densitometry of OCT2 protein expression. Values are expressed as the mean ± SEM, n = 5 in 
each group. (F) Cisplatin-induced DNA damage in the kidney from cisplatin-injected H1RKO 
mice, and cisplatin-injected H1RKO mice with DPH treatment. Left panel: Representative 
images of DNA platination product Pt-(GpG) and DAPI in the kidney sections. Right panels: 
Semi-quantitative analysis of Pt-(GpG) in DNA. Values are expressed as the mean ± SEM. **P
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< 0.01; n = 5 in each group. (F) Platinum content in kidneys 10 min after cisplatin treatment. 
Values are expressed as the mean ± SEM. *P < 0.05; n =9 in each group.
Figure 6. DPH does not inhibit cisplatin-induced cell death in various cancer cell lines. Cisplatin-
induced cell death was not influenced by the DPH treatment in (A) 3LL mice lung carcinoma 
cells, (B) MKN45 human gastric cancer cells, (C) colon26 mouse colon cancer cells and (D) Hela 
human cervical tumor cells. Values are expressed as the mean ± SEM, *P < 0.05, **P < 0.01, n
= 6–12 in each group.
Figure 7. DPH ameliorates cisplatin-induced kidney injury without blocking the therapeutic 
effects in mice bearing Lewis lung carcinoma cells. (A) Changes in tumor volume during the 
observation period. Tumors were measured to determine tumor volume. *P < 0.05, **P < 0.01 
vs. other groups; n = 6–11 in each group. (B) Upper panel: representative extracted tumors. Lower 
panels: tumor volume and weight at the end of the 4 week-period. Mean ± SEM. **p < 0.01 vs.
vehicle group; n = 6–11 in each group (C) Left panel: representative hematoxylin and eosin 
(H&E) staining of kidney sections at 4 weeks after vehicle, cisplatin, or cisplatin-plus-DPH 
treatment. Right panel: quantitative analysis of renal damage scores. Values are expressed as the 
mean ± SEM. *P < 0.05, **P < 0.01; n = 6–9 in each group. (D) mRNA expression levels of 
kidney injury markers (KIM-1 and lipocalin-2) in the kidneys of mice in each group. Values are 
expressed as the mean ± SEM. *P < 0.05, **P < 0.01; n = 6–9 in each group. (E) mRNA 
expression levels of renal fibrosis markers (collagen I and III) in the kidneys of mice in each group. 
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Values are expressed as the mean ± SEM. *P < 0.05, **P < 0.01; n = 6–9 in each group. (F) Left 
panel: representative picrosirius red staining of kidney sections at 4 weeks after vehicle, CDDP, 
or CDDP-plus-DPH treatment. Right panel: quantitative analysis of renal fibrosis area. Values 
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cisplatin-induced nephrotoxicity 
DPH is effective as a novel preventive
medicine against CIN.
Hamano and Ikeda, et al. 2020
Medical big data research
Cisplatin
Anti-tumor effectNephrotoxicity
Search for existing drugs
used concomitantly with
cisplatin
Drug identification Basic research Clinical research
No interferencePrevention
Reduction of CIN in cancer
patients under DPH treatment:
a retrospective cohort study
DPH
Diphenhydramine (DPH) as











Fluconazole            
Lorazepam
Incidence rate of CIN
Comprehensive analysis of
1543 drugs used with cisplatin
Occurrence of CIN
Apoptosis
Pt uptake
Inflammation
Oxidative stress
1416 DPH
Non-users
51 DPH
users
22.4% 6.1% 
DPH use (+)
